Product/Composition:- | Dicloxacillin Suspension |
---|---|
Strength:- | 125 mg/5 mL, 250 mg/5 mL |
Form:- | Powder for Oral Suspension |
Reference Brands:- | Dynapen(US) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Dicloxacillin suspension inhibits bacterial cell wall synthesis by targeting penicillin-binding proteins, causing bacterial lysis. It effectively treats penicillinase-producing staphylococcal infections. Benefits include targeted, effective oral therapy, suitable for pediatric use, rapid bacterial eradication, and good absorption. It provides reliable treatment in children and adults.
Dicloxacillin suspension is approved in the EU and US for treating penicillinase-producing staphylococcal infections, particularly in children. In the EU, brands are regulated by EMA, supported by dossiers demonstrating safety, efficacy, and quality standards. In the US, FDA approval relies on comprehensive clinical data, with generics available. Both regions require detailed dossiers and pharmacovigilance plans for approval and ongoing safety monitoring. For expert assistance with regulatory dossiers, compliance, and registration, visit PharmaTradz. We support seamless market access for dicloxacillin suspension, ensuring adherence to European and American standards for safe, effective antibiotic therapy, especially for pediatric bacterial infections.